Medivation Company Profile (NASDAQ:MDVN)

About Medivation

Medivation logoMedivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MDVN
  • CUSIP: 58501N10
Key Metrics:
  • Previous Close: $81.44
  • 50 Day Moving Average: $77.41
  • 200 Day Moving Average: $61.39
  • 52-Week Range: $26.41 - $81.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 36.36
  • P/E Growth: 1.69
  • Market Cap: $N/A
  • Beta: 0.6
  • Net Margins: -17.24%
  • Return on Equity: 17.57%
  • Return on Assets: 9.63%
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 4.32%
  • Quick Ratio: 4.32%
Additional Links:
Companies Related to Medivation:

Analyst Ratings

Consensus Ratings for Medivation (NASDAQ:MDVN) (?)
Ratings Breakdown: 1 Sell Rating, 15 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $74.39 (8.66% downside)

Analysts' Ratings History for Medivation (NASDAQ:MDVN)
DateFirmActionRatingPrice TargetDetails
10/9/2016BMO Capital MarketsReiterated RatingHoldView Rating Details
9/28/2016Cowen and CompanyReiterated RatingHoldView Rating Details
9/28/2016Canaccord GenuityReiterated RatingBuyView Rating Details
9/14/2016SunTrust Banks Inc.Reiterated RatingNeutralView Rating Details
8/22/2016Maxim GroupSet Price TargetBuy$76.00View Rating Details
8/23/2016Credit Suisse Group AGDowngradeOutperform -> Neutral$81.50View Rating Details
8/23/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
8/22/2016Citigroup Inc.DowngradeBuy -> Neutral$73.00 -> $81.50View Rating Details
8/22/2016WedbushDowngradeOutperform -> Neutral$81.50View Rating Details
8/22/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
8/22/2016Barclays PLCDowngradeOverweight -> Equal Weight$70.00 -> $81.00View Rating Details
8/10/2016Leerink SwannSet Price TargetHold$64.00View Rating Details
8/10/2016Jefferies GroupReiterated RatingHold$56.00 -> $60.00View Rating Details
8/10/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
5/7/2016Royal Bank Of CanadaReiterated RatingSector Perform$40.00 -> $70.00View Rating Details
5/4/2016MizuhoDowngradeNeutral -> Underperform$150.00View Rating Details
5/1/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$44.00View Rating Details
4/4/2016BTIG ResearchReiterated RatingHoldView Rating Details
2/19/2016Bank of America Corp.Initiated CoverageBuy$45.00View Rating Details
1/31/2016William BlairReiterated RatingOutperform$83.00View Rating Details
9/15/2015NomuraInitiated CoverageBuy$140.00View Rating Details
3/25/2015JPMorgan Chase & Co.Boost Price TargetOverweight$130.00 -> $148.00View Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Medivation (NASDAQ:MDVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.27$0.29$214.52 million$206.00 millionViewN/AView Earnings Details
5/5/2016Q116$0.23$0.11$197.01 million$182.50 millionViewListenView Earnings Details
2/25/2016Q415$0.25$0.29$373.85 million$377.74 millionViewListenView Earnings Details
11/5/2015Q315$0.33$0.35$236.70 million$260.70 millionViewN/AView Earnings Details
8/6/2015Q215$0.45$0.58$155.22 million$175.67 millionViewN/AView Earnings Details
5/7/2015Q115$0.27$0.17$149.00 million$129.20 millionViewN/AView Earnings Details
2/25/2015Q414$1.33$1.96$233.19 million$274.70 millionViewN/AView Earnings Details
11/6/2014Q314$0.84$0.96$182.00 million$200.48 millionViewN/AView Earnings Details
8/7/2014Q214$0.24$0.60$126.46 million$148.09 millionViewN/AView Earnings Details
5/8/2014Q114($0.09)($0.18)$94.64 million$87.19 millionViewN/AView Earnings Details
2/27/2014Q413($0.08)$0.03$72.68 million$96.61 millionViewN/AView Earnings Details
1/30/2014Q4($0.14)($0.43)ViewN/AView Earnings Details
11/12/2013Q313($0.26)($0.18)$60.13 million$108.50 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.21)($0.07)$59.35 million$70.15 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.45)($0.36)$38.54 million$46.15 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.52)($0.43)$34.36 million$37.16 millionViewN/AView Earnings Details
11/9/2012Q312($0.03)($0.06)$52.11 million$64.80 millionViewN/AView Earnings Details
8/9/2012$0.23($0.15)ViewN/AView Earnings Details
5/8/2012$1.19$0.01ViewN/AView Earnings Details
2/29/2012($0.25)($0.31)ViewN/AView Earnings Details
11/9/2011($0.31)($0.29)ViewN/AView Earnings Details
8/9/2011($0.25)($0.27)ViewN/AView Earnings Details
5/6/2011($0.24)($0.24)ViewN/AView Earnings Details
3/16/2011($0.17)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Medivation (NASDAQ:MDVN)
Current Year EPS Consensus Estimate: $1.27 EPS
Next Year EPS Consensus Estimate: $2.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20165$0.18$0.26$0.21
Q3 20162$0.24$0.25$0.25
Q4 20162$0.31$0.32$0.32
(Data provided by Zacks Investment Research)


Dividend History for Medivation (NASDAQ:MDVN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Medivation (NASDAQ:MDVN)
Insider Ownership Percentage: 3.54%
Institutional Ownership Percentage: 87.55%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016Andrew Kenneth William PowellSVPSell2,578$60.42$155,762.76View SEC Filing  
5/6/2016Rick BierlyCFOSell10,340$59.76$617,918.40View SEC Filing  
3/14/2016Dawn SvoronosDirectorSell6,000$38.90$233,400.00View SEC Filing  
3/4/2016David HungCEOSell5,085$41.10$208,993.50View SEC Filing  
3/4/2016Mohammad HirmandInsiderSell1,525$41.10$62,677.50View SEC Filing  
3/4/2016Rick BierlyCFOSell2,998$40.00$119,920.00View SEC Filing  
2/4/2016David HungCEOSell6,350$31.18$197,993.00View SEC Filing  
1/19/2016Clarence Patrick MachadoDirectorSell75,000$37.34$2,800,500.00View SEC Filing  
1/4/2016Joseph M LobackiInsiderSell3,065$46.50$142,522.50View SEC Filing  
12/14/2015W Anthony VernonDirectorBuy15,000$40.69$610,350.00View SEC Filing  
12/3/2015David HungCEOSell10,950$43.10$471,945.00View SEC Filing  
12/3/2015Mohammad HirmandInsiderSell1,075$43.40$46,655.00View SEC Filing  
9/25/2015Clarence Patrick MachadoDirectorSell71,980$42.36$3,049,072.80View SEC Filing  
9/8/2015Dawn SvoronosDirectorSell3,100$89.15$276,365.00View SEC Filing  
6/4/2015Clarence Patrick MachadoDirectorSell36,000$117.43$4,227,480.00View SEC Filing  
5/20/2015Rick BierlyCFOSell1,000$130.00$130,000.00View SEC Filing  
5/5/2015Rick BierlyCFOSell1,615$125.00$201,875.00View SEC Filing  
5/4/2015Rick BierlyCFOSell2,170$124.70$270,599.00View SEC Filing  
4/15/2015Rick BierlyCFOSell3,000$132.20$396,600.00View SEC Filing  
3/16/2015Jennifer J RhodesInsiderSell1,390$130.92$181,978.80View SEC Filing  
3/2/2015David HungCEOSell100,891$120.83$12,190,659.53View SEC Filing  
3/2/2015Dawn SvoronosDirectorSell3,350$119.75$401,162.50View SEC Filing  
3/2/2015Jennifer J RhodesInsiderSell2,000$122.00$244,000.00View SEC Filing  
2/27/2015Kathryn E FalbergDirectorBuy25,000$117.67$2,941,750.00View SEC Filing  
2/26/2015David HungCEOSell19,109$120.12$2,295,373.08View SEC Filing  
2/26/2015Jennifer J RhodesInsiderSell3,089$119.29$368,486.81View SEC Filing  
2/4/2015David HungCEOSell3,190$100.48$320,531.20View SEC Filing  
1/27/2015Clarence Patrick MachadoDirectorSell36,000$105.32$3,791,520.00View SEC Filing  
1/20/2015David HungCEOSell100,000$108.14$10,814,000.00View SEC Filing  
12/3/2014Clarence Patrick MachadoDirectorSell1,580$113.00$178,540.00View SEC Filing  
12/3/2014David HungCEOSell5,420$113.00$612,460.00View SEC Filing  
9/18/2014Lynn SeelyInsiderSell55,000$98.47$5,415,850.00View SEC Filing  
9/9/2014Lynn SeelyInsiderSell20,000$94.60$1,892,000.00View SEC Filing  
8/27/2014Lynn SeelyInsiderSell20,000$89.42$1,788,400.00View SEC Filing  
8/13/2014Lynn SeelyInsiderSell20,000$83.62$1,672,400.00View SEC Filing  
8/12/2014Lynn SeelyInsiderSell25,500$83.02$2,117,010.00View SEC Filing  
7/22/2014Lynn SeelyInsiderSell7,500$73.96$554,700.00View SEC Filing  
7/2/2014Lynn SeelyInsiderSell12,000$79.02$948,240.00View SEC Filing  
6/18/2014Lynn SeelyInsiderSell15,000$74.75$1,121,250.00View SEC Filing  
2/18/2014Clarence Patrick MachadoCFOSell40,000$82.79$3,311,600.00View SEC Filing  
2/11/2014Clarence Patrick MachadoCFOSell40,000$80.83$3,233,200.00View SEC Filing  
2/5/2014Clarence Patrick MachadoCFOSell40,000$73.46$2,938,400.00View SEC Filing  
1/28/2014Clarence Patrick MachadoCFOSell40,000$75.43$3,017,200.00View SEC Filing  
1/27/2014David HungCEOSell150,000$73.50$11,025,000.00View SEC Filing  
1/21/2014Clarence Patrick MachadoCFOSell40,000$76.29$3,051,600.00View SEC Filing  
1/21/2014Jennifer RhodesInsiderSell14,000$76.28$1,067,920.00View SEC Filing  
12/3/2013Clarence Patrick MachadoCFOSell5,425$62.66$339,930.50View SEC Filing  
12/3/2013David HungCEOSell15,050$62.61$942,280.50View SEC Filing  
10/24/2013Cheryl CohenInsiderSell50,000$64.25$3,212,500.00View SEC Filing  
8/2/2013Cheryl CohenInsiderSell25,000$59.31$1,482,750.00View SEC Filing  
7/5/2013David HungCEOSell30,885$55.45$1,712,573.25View SEC Filing  
7/3/2013Cheryl CohenInsiderSell25,000$54.01$1,350,250.00View SEC Filing  
10/4/2012David HungCEOSell50,000$57.92$2,896,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Medivation (NASDAQ:MDVN)
DateHeadline logoBillionaire Ken Fisher Loves These Dividend Stocks (NASDAQ:MDVN) - October 21 at 6:07 PM
News IconStock Chatter: Medivation, Inc. (NASDAQ:MDVN) Price Target Update - Recall News (NASDAQ:MDVN) - October 19 at 11:04 AM
News IconMedivation, Inc. (NASDAQ:MDVN) – Broker Update - NewsDen (NASDAQ:MDVN) - October 19 at 11:04 AM logoMedivation Has Returned 30.1% Since SmarTrend Recommendation (MDVN) (NASDAQ:MDVN) - October 17 at 6:00 PM
News IconMedivation, Inc. (NASDAQ:MDVN) Updated Broker Price Targets ... - The De Soto Edge (NASDAQ:MDVN) - October 16 at 5:53 PM logoAnalyst Sees Risk Of Major M&A Action; Downgrades Pfizer Inc. (PFE) Price Target To $36 (NASDAQ:MDVN) - October 14 at 5:55 PM
News IconNew Analyst Ratings On Medivation, Inc. (NASDAQ:MDVN) - NewsDen (NASDAQ:MDVN) - October 13 at 9:40 AM logoNew Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly Improves Time to PSA Progression in Advanced Prostate Cancer, Compared with Placebo (NASDAQ:MDVN) - October 9 at 10:26 AM
News IconPre-Movers Stocks In Analysts Rate: Medivation, Inc. (NASDAQ:MDVN), Envision Healthcare Holdings, Inc. (NYSE ... - Street Wise Report (press release) (blog) (NASDAQ:MDVN) - October 7 at 11:10 AM
News IconNotable Runner: Institutional Investors Are Buying Medivation Inc (NASDAQ:MDVN) - Post News (NASDAQ:MDVN) - October 6 at 11:35 AM
News IconMedivation Inc (NASDAQ:MDVN) pursues AstraZeneca plc (ADR) (NYSE:AZN) after the exit of Sanofi SA (ADR) (NYSE ... - (NASDAQ:MDVN) - October 6 at 11:35 AM
News IconUnusual Stocks Mover Hurt By Street Views: Medivation, Inc. (NASDAQ:MDVN), Provectus Biopharmaceuticals, Inc ... - Street Wise Report (press release) (blog) (NASDAQ:MDVN) - October 6 at 11:35 AM
News IconStocks Sparking Bullish Stampede across Wall Street: Medivation (NASDAQ:MDVN), Celldex Therapeutics (NASDAQ ... - Street Wise Report (press release) (blog) (NASDAQ:MDVN) - October 3 at 5:44 PM logoMedivation Shares Up 30.1% Since SmarTrend's Buy Recommendation (MDVN) (NASDAQ:MDVN) - September 30 at 6:14 PM logoMedivation, Inc. (NASDAQ:MDVN) Is Expected To Post EPS Of $0.43 - (NASDAQ:MDVN) - September 30 at 11:19 AM logoA Look at the Pfizer-Medivation Deal (NASDAQ:MDVN) - September 29 at 6:03 PM logoCompany Update (NASDAQ:MDVN): Medivation Inc Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016 (NASDAQ:MDVN) - September 29 at 11:10 AM logoMedivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016 (NASDAQ:MDVN) - September 28 at 5:51 PM
News IconNoticeable Stock: Masco Corporation (NYSE:MAS), Medivation, Inc. (NASDAQ:MDVN) - Newburgh Press (NASDAQ:MDVN) - September 28 at 11:02 AM logoPfizer (PFE) Closes Medivation (MDVN) Acquisition - (NASDAQ:MDVN) - September 28 at 11:02 AM logoMEDIVATION, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Dis (NASDAQ:MDVN) - September 28 at 11:01 AM logoPfizer Completes Acquisition of Medivation (NASDAQ:MDVN) - September 28 at 11:01 AM
News IconBlog Coverage US Pharma Giant Pfizer to Whole as one Complete Unit (NASDAQ:MDVN) - September 27 at 10:41 AM
News IconBiotech Stocks Worth Chasing: Mast Therapeutics, Inc. (MSTX ... - The Independent Republic (NASDAQ:MDVN) - September 26 at 6:04 PM
News IconHC Stocks Assessment! Medivation Inc (MDVN), Pfizer Inc. (NYSE:PFE) - share market updates (press release) (NASDAQ:MDVN) - September 26 at 6:04 PM
News IconAnalysts Rating Trending Stocks: Medivation Inc (NASDAQ:MDVN ... - Money News (NASDAQ:MDVN) - September 26 at 6:04 PM logoBillionaire James Dinan’s York Capital Initiated Stakes in These Companies (NASDAQ:MDVN) - September 26 at 10:45 AM
News IconPfizer expects to close Medivation buyout in 3Q (NASDAQ:MDVN) - September 23 at 5:43 PM logoPfizer Gets U.S. Regulatory Approval For Medivation Takeover (NASDAQ:MDVN) - September 23 at 10:47 AM logoPfizer (PFE) Says HSR Act Waiting Period in Medivation (MDVN) Acquisition has Expired (NASDAQ:MDVN) - September 23 at 10:47 AM
News IconInvestor News: Lawsuit against Buyout of Medivation Inc (NASDAQ:MDVN) filed (NASDAQ:MDVN) - September 23 at 10:47 AM logoTrader Alert: Medivation, Inc. (MDVN), TherapeuticsMD, Inc. (TXMD), American Capital, Ltd. (ACAS) (NASDAQ:MDVN) - September 23 at 10:47 AM logo8:31 am Medivation: Pfizer (PFE (NASDAQ:MDVN) - September 23 at 10:47 AM logoPfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation (NASDAQ:MDVN) - September 23 at 10:47 AM logoShares of MDVN Up 29.4% Since Uptrend Call on Shares (NASDAQ:MDVN) - September 22 at 5:49 PM
News IconHC Stocks to Path! Exelixis, Inc. (NASDAQ:EXEL), Medivation Inc ... - share market updates (press release) (NASDAQ:MDVN) - September 22 at 10:54 AM
News IconHC Stocks Movements! Novavax, Inc. (NVAX), Medivation Inc (NASDAQ:MDVN) - share market updates (press release) (NASDAQ:MDVN) - September 22 at 10:54 AM
News IconActive biotech company shares in the news: Medivation, Inc. (NASDAQ:MDVN), Opko Health, Inc. (NASDAQ:OPK) - The Voice Registrar (NASDAQ:MDVN) - September 22 at 10:54 AM
News IconNews review of 2 biotech stocks: Medivation (NASDAQ:MDVN), Opko Health (NASDAQ:OPK) - The Voice Registrar (NASDAQ:MDVN) - September 21 at 10:12 AM
News IconHC Stocks Highlights! Medivation Inc (MDVN), Array Biopharma Inc (NASDAQ:ARRY) - share market updates (press release) (NASDAQ:MDVN) - September 21 at 10:12 AM logoBritish pharma group GSK appoints new CEO (NASDAQ:MDVN) - September 20 at 11:16 AM
News IconHigh Market Cap Stock of the Day – Medivation, Inc. (NASDAQ:MDVN) (NASDAQ:MDVN) - September 19 at 6:05 PM logoAfter Losing Medivation, Who Is Gilead Going After Next? (NASDAQ:MDVN) - September 19 at 4:54 PM
News IconMedivation, Inc.'s (MDVN): Keep an eye on Active stock of Friday - Hot Stocks Point (NASDAQ:MDVN) - September 19 at 10:38 AM
News IconHC Stocks Alerts! Celgene Corporation (CELG), Medivation Inc (NASDAQ:MDVN) - share market updates (press release) (NASDAQ:MDVN) - September 19 at 10:38 AM
News IconTrading the Biotech News: Medivation, Inc. (NASDAQ:MDVN), Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) - The Voice Registrar (NASDAQ:MDVN) - September 19 at 10:38 AM
News IconStocks Rallying on Glossy Earnings: Medivation, Inc. (NASDAQ:MDVN), Jazz Pharmaceuticals Public (NASDAQ:JAZZ) - Street Wise Report (press release) (blog) (NASDAQ:MDVN) - September 16 at 5:53 PM
News IconHC Stocks to Path= Novavax, Inc. (NASDAQ:NVAX), Medivation Inc ... - share market updates (press release) (NASDAQ:MDVN) - September 16 at 5:53 PM
News IconMedivation, Inc. (MDVN), Raptor Pharmaceuticals Corp. (RPTP) - Cosumnes Connection (subscription) (NASDAQ:MDVN) - September 16 at 5:53 PM
News IconActive biotech company shares in the news: Novavax, Inc. (NASDAQ:NVAX), Medivation, Inc. (NASDAQ:MDVN) - The Voice Registrar (NASDAQ:MDVN) - September 16 at 9:43 AM


Medivation (NASDAQ:MDVN) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff